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SUMMARY 
Clobazam as a twice-a-day dosage (10 mg-20 mg) regimen and Diazepam in a thrice-a-da y sche-
dule (j mg-5 mg-5 mg) were bot"i effective in controlling moderate to severe anxiety neurosis. 83 pitients 
were studied in a controlled, randomised, double-blind trial. Patients received active drug for the first six-
weeks and placebo for the next two weeks. Weekly evaluation was performed clinically for anxiolytic effect 
as wel 1 as effect on motor coordination studied on the PursuitRotor. 
Clobazam did not significantly differ from Diazepam in the dosage schedules studied. At the end 
of the two-week placebo treatment period, patients on Clobazim showed more improvement. Motor coor-
dination was not impaired in both treatment groups. Clobazam treated patients had better motor perfor-
mance at the end of the 14-day post-treatment placebo period. Side effects were reported with equal fre-
quency in both the populations. 
Newer benzodiazepines are being 
introduced for the treatment of anxiety 
neurosis. The effort to establish more 
than "me too" drugs is always present. 
In clinical practice an achievement in 
-less- side effects or better patient comp-
liance would be a significant contribu-
tion to therapeutics. 
Clobazam is a relatively new ben-
zodiazepine, which is being investigated 
in India* Previous studies (de Figuei-
redo et.al, 1981; Doongaji et aL, 1978) 
have shown the drug has good anxiolytic 
effect even during withdrawal from 
treatment. In these studies a dose of 
30 mg in equally divided doses per day 
has been studied. In view of its pro-
longed efficacy, we were interested to 
study the anxiolytic efficacy of 30 mg 
Clobazam as two divided doses of 10 
mg and 20 mg per day. It was also 
important to determine if the adminis-
tration of 20 mg Clobazam at night, 
could have any effect on motor co-
ordination. 
Clobazam is unique in its structural 
relationship to the general class of 
benzodiazepines. It has a nitrogen 
atom in the "V position, instead of the 
'4' position, which may contribute 
to the differential effects on the desired 
tranquillising, or taming behaviour and 
the undesired effects on motor coordi-
nation. 
The trial was specially designed to 
study the efficacy of the twice-a-day 
regimen of Clobazam, any effects on 
motor coordination, and the anxiolytic 
activity during drug withdrawal. 
METHODOLOGY 
Eighty-three adult outpatients dia-
gnosed as anxious neurotics entered the 
study. By random allocation, patients 
received either Clobazam as 10 mg 
at morning and 20 mg at night or 
Diazepam as 5 mg three times a day. 
To maintain double-blind conditions, 
the double-dummy technique of drug 
administration was used. Each patient 
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therefore received numerically two cap-
sules three times a day, corresponding 
to the respective doses of Clobazam and 
Diazepam. 
Patients with clinical evidence of 
severe hepatic, renal or cardiovascular 
pathology, or organic brain damage, 
were excluded. A history of drug abuse, 
affective psychosis or benzodiazepine 
sensitivity also excluded patients from 
entry. Pregnancy or its possibility did 
not permit inclusion of such females 
into study. Patients who were already 
on anxiolytic therapy underwent a one 
week wash out on placebo. 
For inclusion, a patient had to be 
diagnosed as an anxious neurotic, with 
a score of at least 14 on the Hamilton 
Anxiety Rating Scale (HARS) (Hamil-
ton, 1959), as well as at least two on the 
items of anxious mood and general 
somatic (muscular and sensory). Treat-
ment was administered by randomisa-
tion in packets specially packed for 
each patient for the 7-days of the week. 
Active drug treatment was for six-
weeks followed by two-weeks treatment 
on placebo. 
Efficacy evaluation was done at the 
end of each week on the HARS, by the 
Research Worker, as well as on the 
Clinical Global Impression Scale (CGI) 
(ECDEU Assessment Manual, 1970) 
by the principal investigator. 
At each evaluation period, motor 
coot dination was tested on the Koerth's 
Pursuit Rotor. Patients underwent 
each time a familiarisation trial run 
(30 sees). Subsequently, the mean of 
3 trials was considered as an assessment. 
RESULTS 
Demography 
Out of 83 patients who entered 
the study, 40 received Clobazam, and 
43 received Diazepam. Groups were 
comparable for demographic variables 
as seen in Table I. Seven patients (5 in 
Clobazam group and 2 in Diazepam 
group) had duration of illness less than 1 
month while 18 patients (8 in Clobazam 
group and 10 in Diazepam group) had 
duration more than 2years. These 
patients were also included in the 
analysis. 
TABLE 1 —Demograpic Variables 
Clobazam Diazepam 
Patients entered in study 40 43 
Drop-outs 8 15 
Available for analysis 32 28 
Sex 
Male 17 17 
Female 15 11 
Age (years) 30.56±1.64 34.78±2.41 
Weight (kgs) 53. 3± 1.51 56.38±2 .16 
Clinical Assessment 
Both drugs significantly reduced 
the basal score of anxiety on the HARS 
at the end of 6 weeks treatment. The 
onset of activity was seen for both drugs 
at the end of 8 days. At the end of 6 
weeks of treatment, patients on Cloba-
zam showed 71 per cent improvement 
and those on Diazepam improved by 67 
per cent (Table 2). 
At the end of further 2 weeks 
during which patients received placebo, 
the Clobazam treated group continued 
to improve by 11 per cent. Further 
improvement in the Diazepam series 
was 4 per cent. 
The HARS was subjected to further 
analysis on the clusters of psychic and 
somatic anxiety. By Wilcoxon's Signed 
RankTest, significant improvement was 
seen for both groups (starting with week 
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TABLE 2—Percentage improvement on total scores of HARS 
Treatment period Placebo period 
Day 8 Day 15 Day 22 Day 29 Day 36 Day 43 Day 50 Day 57 
Clobazam 38.20 52.23 61.00 64.00 68.50 71.00 2.68 11.00 
Diazepam 41.45 49.48 54.50 61.00 63.08 67.00 2.75 4.00 
Diflereiices were not significant at any evaluation period. Onset of activity seen on Day 8 for both 
drugs (p<0.001). Percentage reduction in placebo period is with respect to Day 43. 
On the cluster of somatic anxiety, 
Clobazam produced an improvement of 
70 per cent and Diazepam an improve-
ment of 67 per cent (Table 3). 
TABLE 3—Percentage improvement on psy-
chic and somatic anxiety clusters 
Clobazam Diazepam 
Psychic Somatic Psychic Somatic 
Day 8 
Day 15 
Day 22 
Day 29 
Day 36 
Day 43 
Day 50 
Day 57 
39.74 
52.90 
61.33 
64.03 
69.00 
72.00 
—0.67 
+8.57 
35.97 
51.23 
59.40 
64.00 
68.00 
70.00 
4-7.2 
+ 14 
41.36 
48.58 
52.52 
59.52 
63.00 
67.00 
+0.66 
+ 4.93 
41.59 
51.00 
57.46 
62.54 
63.49 
67.30 
+5.8 
—2.25 
•Differences not significant at any evaluation. 
Percentage reduction in placebo period is with res-
pect to day 43. 
On the psychic anxiety cluster, the 
percentage improvement after Clo-
bazam treatment was 72 per cent, 
and following Diazepam 67 per cent 
(Table 3). 
The anxiolytic effect of Clobazam 
was better than Diazepam during the 
2 week drug withdrawal period. The 
cluster of somatic anxiety continued to 
improve by 14 per cent after Clobazam 
and by 2 per cent after Diazepam. 
Psychic anxiety was further reduced 
by 8 per cent with Clobazam and by 
4 per cent with Diazepam, at the end 
of the post-drug placebo treatment 
(Table 3). 
On the HARS, significant (p<0.05) 
improvement was observed in Clobazam 
treated patients for the symptoms insom-
nia, general somatic (muscular) on Day 
22, and for depressed mood on Days 
22 and 29. Patients who received Dia-
zepam improved significantly (p<0.05) 
on Days 8 and 15, for respiratory and 
gastrointestinal symptoms. 
To assess continuing drug effect 
during the 2 week period on placebo, 
the Sum of Improvement Scores (SIS) 
was calculated on the principle of Sum 
of Reduction Scores used by Doongaji 
et al. (1978). 
Clobazam treated patients had a 
higher sum of improvement on the 
total HARS, as well as %n the clusters of 
psychic and somatic anxiety (Table 4). 
During this period, six variables of the 
HARS—fear, intellect, depressed mood, 
general somatic (sensory), cardiovas-
cular and respiratory continued to res-
pond to Clobazam. Against this, only 
two symptoms, gastrointestinal and 
behaviour at interview (general) showed 
improvement in patients on Diazepam. 
In both the treatment groups, continued 
therapeutic effect was seen for insomnia 
and general somatic (muscular). 144  GURMEET SINGH et al. 
TABLE 4—Sum of improvement scores du-
ringpost-treatment placebo period 
Clobazam Diazepam 
(N=30) (N=24) 
Total HARS 32 10. 
Anxiety psychic 9 8 
Anxiety somatic 23 8 
On the Clinical Global Improve-
ment (CGI) Scale, more patients sho-
wed moderate and marked improve-
ment on Clobazam. On Days 50 and 
57, signiiicantly more patients showed 
modrate and marked improvement after 
receiving Clobazam (p<0.06) (Table 5). 
TABLE 5—Clinical Global Impression Scale 
(CGIS) (Patients who showed 
moderate and marked improve-
ment) 
Day Clobazam Diazepam 
(N=28) (N=28) 
8 20 17 
13 26 20 
22 27 21 
29 29 23 
36 * 30 ' 22 
43 30 22 
30 31 22* 
57 30/30 18/24** 
*p =0.0686 (by Fisher's Test) 
**p=0.0104 (by Fisher's Test) 
Motor performance 
Performance was assessed as 10 
per cent if contact on target could be 
made for 30 seconds. The percentage 
of total time was calculated and tested 
by Wilcoxon's Sum of Rank Test for 
both populations. Both the treatments 
significantly improved performance. 
The Sum of Improvement Scores 
of motor performance on the Pursuit 
Rotor was calculated for both drug 
treated groups during withdrawal 
based on average for the populations. 
The Sum of Improvement Scores in 
patients on Clobazam was 78 and in 
the Diazepam treated patients was 33, 
at the end of the 2 week drug free 
period (Table 6). Thus motor perfor-
mance continues to improve in both 
Clobazam and Diazepam groups after 
stopping the anxiolytic medication, the 
improvement being relatively more in 
subjects who were on Clobazam. 
TABLE 6—Status of patients on Pursuit 
Rotor during placebo period 
(Day 43-57) 
Clobazam Diazepam 
Total 28 23 
Patients who improved 28 23 
(Improvement above 75%) (9) (2) 
Patients who worsened 3 5 
Patients with no change 1 2 
Sum of Improvement Score 78.27 33.23 
SIDE EFFECTS 
Drowsiness was the commonest side 
effect reported. 22 out of 32 patients on 
Clobazam and 19 out of 28 patients on 
Diazepam complained of drowsiness as 
side effect (Table 7). Both drugs did 
not adversely affect any clinical che-
mistry parameters. A CONTROLLED CLINICAL TRIAL OF A NEW ANXIOLYTIC  145 
TABLE 1— Patients who reported side effects 
Clobazam Diazepam 
(n=32) (n=28) 
(68.75%) 
C. ,V. S. 
Drowsiness 22 \ 
Giddiness 4; 
Heaviness in eyes 1 I 
Trembling 1 
G. I. T. 
Constipation 0. 
Bad taste in mouth 1 
Increased thirst 1 i 
Dryness of mouth 1/ 
SKIN 
Itching — 
MISCELLANEOUS 
Heavy voice 1(3.1%) 
Disinterest in work 
Falling down on walking 
'
9» 
3' 
9.38% 
V (67.86%) 
I- 14.29% 
1 (3.5%) 
:i 
(7.14%) 
DISCUSSION 
Data from the study on both the 
clinical as well as the motor performance 
testing show Clobazam is an effective 
agent, with good maintenance of anxio-
lysis in the twice-a-day dosage regimen. 
On the HARS as well as on the two 
clusters of psychic and somatic anxiety, 
both drugs show good anxiolytic effect 
by Day 8. Patients who received 
Clobazam showed a trend for better 
maintenance of therapeutic effect till 
the end of the two-week post-treatment 
period on placebo. 
. Both de Figueiredo et al. (1981) 
and Doongaji and associates (1978) 
observed this phenomenon after 4 weeks 
treatment with Clobazam followed by 
one week on placebo. Our study de-
monstrates that the drug has prolonged 
anxiolytic activity long after treatment 
is stopped. This action ensures the 
smooth transition to the non-drug state, 
when treatment requires to be stopped 
or as is encountered in common prac-
tice when patients forget to take their 
medication. Clobazam apparently has 
a strong carry over effect which is obser-
ved clinically on the HARS and both 
clusters of psychic and somatic anxiety. 
On motor performance testing, the 
better trend for improving function is 
observed during the post treatment 
period in patients who received Cloba-
zam. This could be attributed to the 
good anxiolysis with Clobazam affecting 
especially somatic symptoms like tre-
mor. The corresponding somatic va-
riable, general somatic (muscular) also 
showed significant improvement after 
treatment with Clobazam, and conti-
nued to improve during withdrawal. 
The good carry over effect of 
Clobazam may be due to its active 
metabolite. The parent compound it-
self has a long-life of 18 hours. Pharma 
cological studies have shown the meta-
bolite N-desmethyl Clobazam is active 
in animal experimentation (Fielding 
and Hoffman, 1979) and has receptor 
binding potency similar to the parent 
compound (Hunt, 1979). 
From pharmacokinetic studies, the 
half-life of the metabolite is 36-36 
hours, and it accumulates to a steady-
state level about 8 times higher than 
the parent compound (Rupp et al., 
1979). This data explains good mainte-
nance anxiolytic effect of Clobazam and 
also the improvement which was seen 
during the withdrawal stage. 
Throughout evaluation,higher trends 
have been observed on anxiolytic effect, 
motor coordination and maintenance of 
therapeutic response after treatment was 
stopped in patients who have received 
Clobazam. The results are clinically 
significant, especially in the light of 
comparisons made between two active 146  GURMEET SINGH, et at. 
drugs than between active drug and 
placebo. 
Drowsiness occurred with equal fre-
quencey in both the treatment groups. 
It seemed worthwhile to study the rea-
sons for drop-outs where available to 
ascertain any cause-effect relation to 
the drugs under study. Out of the 8 
drop-outs who received Clobazam, only 
one complained of severe drowsiness. 
5 patients out of 15 on Diazepam drop-
ped out due to drowsiness. 
This trial suggests a dose of Clo-
bazam as 10 mg at morning and 
20 mg at night does not produce any 
detrimental effect on motor coordi-
nation with respect of Diazepam (15 
mg) in 3 equally divided doses. The 
effect of Globazam is well maintained 
after treatment is discontinued, so that 
there is no risk of a worsening of anxiety, 
in the event of a patient forgetting to 
take medication. The twice-a-day sche-
dule is a forward step in improving 
patient compliance. 
Perhaps Clobazam can be called a 
"better" anxiolytic, since it meets the 
conditions for "better" as defined by 
Vinar (1973). "It affects some symp-
toms in a more intensive way, its thera-
peutic effects endure longer, it has 
fewer side-effects, and is simpler to 
administer." 
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